Manufacturers report positive data for C21 from the ATTRACT clinical study in patients with COVID-19

In the study, this low molecular weight angiotensin II type 2 receptor agonist reduced the risk of needing oxygen at the end of treatment by 40%. Treatment also appeared to be well tolerated.

Source:

Biospace Inc.